Skip to main content
60°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exelixis, Inc.
< Previous
1
2
3
4
Next >
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
May 30, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
May 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
May 03, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
May 01, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
April 25, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Advances Board Refreshment Plan
April 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Reiterates Commitment to Shareholder Value Creation
April 05, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces $550 Million Share Repurchase Program
March 20, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
March 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
March 02, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
February 28, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
February 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
February 02, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
January 24, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Update on Patent Litigation with MSN Laboratories
January 19, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
January 08, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
January 03, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
December 22, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
December 08, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
December 08, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
November 30, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
November 10, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
November 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
CTLT
EXEL
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
November 01, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
November 01, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 01, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
October 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
October 18, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.